Cargando…
Changes in(18)F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2000
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374563/ https://www.ncbi.nlm.nih.gov/pubmed/10917538 http://dx.doi.org/10.1054/bjoc.2000.1342 |
| _version_ | 1782154482768936960 |
|---|---|
| author | Price, P |
| author_facet | Price, P |
| author_sort | Price, P |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2374563 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2000 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-23745632009-09-10 Changes in(18)F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got? Price, P Br J Cancer Editorial Nature Publishing Group 2000-07 2000-07-03 /pmc/articles/PMC2374563/ /pubmed/10917538 http://dx.doi.org/10.1054/bjoc.2000.1342 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Editorial Price, P Changes in(18)F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got? |
| title | Changes in(18)F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got? |
| title_full | Changes in(18)F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got? |
| title_fullStr | Changes in(18)F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got? |
| title_full_unstemmed | Changes in(18)F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got? |
| title_short | Changes in(18)F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got? |
| title_sort | changes in(18)f-fdg uptake measured by pet as a pharmacodynamic end-point in anticancer therapy. how far have we got? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374563/ https://www.ncbi.nlm.nih.gov/pubmed/10917538 http://dx.doi.org/10.1054/bjoc.2000.1342 |
| work_keys_str_mv | AT pricep changesin18ffdguptakemeasuredbypetasapharmacodynamicendpointinanticancertherapyhowfarhavewegot |